Julia Shi, MD
Internal Medicine · New Haven, CTNPI 1972513125
Payments from drug & device makers
Across 158 payments — averaging $56.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- AbbVie$748
- Indivior Inc.$330
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
- Intersect ENT, Inc.$264
- Boehringer Ingelheim$204
- plus $985 from 16 others
What the payments were for
- Consulting fees$4,05546%
- Travel & lodging$1,37715%
- Food & beverage$3,45939%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 32 | $6,093 |
| AbbVie(2 entities) | 38 | $748 |
| Indivior Inc. | 13 | $330 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $267 |
| Intersect ENT, Inc. | 2 | $264 |
| Boehringer Ingelheim | 8 | $204 |
| Pfizer | 12 | $169 |
| AstraZeneca | 3 | $153 |
| Sanofi | 1 | $125 |
| Medtronic | 1 | $124 |
| Orexo US, Inc. | 6 | $96 |
| Alkermes, Inc. | 5 | $87 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Neos Therapeutics, LP | 2 | $35 |
| MDD US Operations, LLC | 1 | $30 |
| Kaleo, Inc. | 2 | $26 |
| GSK | 1 | $20 |
| Viiv Healthcare Company | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,892 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 18 | $24,397 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 154 | $23,288 |
| OzempicSemaglutide | 12 | $15,034 |
| JardianceEmpagliflozin | 14 | $14,533 |
| EliquisApixaban | 11 | $9,158 |
| LinzessLinaclotide | 13 | $6,860 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $1,420 |
| Clonazepam | 138 | $1,407 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,399 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,086 |
| Celecoxib | 22 | $1,077 |
| Oxycodone Hcl | 83 | $1,025 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 24 | $748 |
| Quetiapine Fumarate | 19 | $582 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 32 | $519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $153 | $24,39718 claims |
| Boehringer IngelheimJardiance | $204 | $14,53314 claims |
| PfizerEliquis | $169 | $9,15811 claims |
| AbbVieLinzess | $748 | $6,86013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Haven
- Nancy BrownNew Haven$2.8M
- Michael SchilskyNew Haven$601K
- Marina SilveiraNew Haven$406K
- Stephen BaldassarriNew Haven$189K
- Charles Dela CruzNew Haven$161K
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Maryam GondalNew Haven$114K
- Sandra SpringerNew Haven$77K
- Marcella SmithNew Haven$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.